<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a high incidence of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in patients entered into the preceding Medical Research Council <z:hpo ids='HP_0011010'>Chronic</z:hpo> Lymphocytic <z:mpath ids='MPATH_336'>Leukaemia</z:mpath> Pilot study of autografting [corrected] Of 115 newly diagnosed patients treated with fludarabine, 65 patients proceeded to autologous transplant </plain></SENT>
<SENT sid="1" pm="."><plain>Conditioning was <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and total body irradiation in 49 (75%) patients and chemotherapy in 12 (18%) </plain></SENT>
<SENT sid="2" pm="."><plain>Ten patients have developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; eight had undergone an autograft </plain></SENT>
<SENT sid="3" pm="."><plain>Five-year actuarial risk of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> postautograft was 12.4% (95% confidence interval, 2.5-24%) </plain></SENT>
<SENT sid="4" pm="."><plain>No analysed potential risk factor was predictive for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> development </plain></SENT>
<SENT sid="5" pm="."><plain>We hypothesise that potential causative factors are fludarabine, low cell dose and transplant conditioning </plain></SENT>
</text></document>